Hodgkin Lymphoma Clinical Trials

37 studies are recruiting for hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

   A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Phoenix, Goodyear, Arizona

   Locations

   4 in total

   Run by

   VIVUS LLC

   See if you can join NCT06915246 on ClinicalTrials.gov

2. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

3. Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

   The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce treatment-related side effects.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT05839210 on ClinicalTrials.gov

4. Mozobil for Autologous Hematopoietic Stem Cell Transplantation

   This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07188090 on ClinicalTrials.gov

5. Auto Stem Cell Transplant for Lymphoma Patients

   This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

   Stage

   Phase 2

   Ages

   Up to 75

   Site

   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03125642 on ClinicalTrials.gov

6. BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

   The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinic…

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT07002216 on ClinicalTrials.gov

7. Two Step Haplo With Radiation Conditioning

   This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031897 on ClinicalTrials.gov

8. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

9. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

10. AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

    Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

    Stage

    Phase 2

    Ages

    0 to 30

    Site

    New York Medical College, Valhalla, New York

    Run by

    Mitchell Cairo

    See if you can join NCT04099966 on ClinicalTrials.gov

11. Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

    The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (c…

    Stage

    Phase 2

    Ages

    3 to 39

    Site

    University of Flordia, Gainsville, Florida

    Locations

    3 in total

    Run by

    New York Medical College

    See if you can join NCT05253495 on ClinicalTrials.gov

12. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

    Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

    Stage

    Phase 1

    Ages

    1 to 21

    Site

    Children's Hospital Los Angeles, Los Angeles, California

    Locations

    31 in total

    Run by

    Therapeutic Advances in Childhood Leukemia Consortium

    See if you can join NCT05476770 on ClinicalTrials.gov